RxDoctor Payments Data

Sahai Donaldson

Pulmonary Disease · Orlando, FLNPI 1548716335

Payments from drug & device makers

$1,721in general payments, 2019–2025

Across 82 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$371
  • Merck$267
  • AstraZeneca$243
  • United Therapeutics Corporation$138
  • AbbVie$125
  • Mylan Specialty L.p.$109
  • plus $469 from 12 others

What the payments were for

  • Food & beverage$1,721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,721 in reported general payments places this provider in the 35th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$75,198
Medicare patients
227
Services billed
795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter218$160,676
Breztri AerosphereBudesonide/Glycopyr/Formoterol68$41,054
Stiolto RespimatTiotropium Br/Olodaterol Hcl42$20,716
Spiriva RespimatTiotropium Bromide26$17,493
Combivent RespimatIpratropium/Albuterol Sulfate24$15,775
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$6,297
Albuterol Sulfate HfaAlbuterol Sulfate213$5,448
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,054
Ventolin HfaAlbuterol Sulfate14$898
Prednisone129$536
MethotrexateMethotrexate Sodium14$511
Levalbuterol Tartrate HfaLevalbuterol Tartrate12$504
Levocetirizine Dihydrochloride47$367
Azithromycin27$182
Levofloxacin11$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$371$166,973230 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$46$53,98492 claims
AstraZenecaBreztri Aerosphere$243$41,05468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →